This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Monday, March 24, 2014
Gilead's Sovaldi -Getting a drug company to cut its price is harder than it sounds
One Of Pharma's Biggest Enemies Goes After The Future's Best-Selling Drug
Getting a drug company to cut its price is harder than it sounds. Haines
spoke on a conference call with ISI clients Friday about Waxman’s
probable intent of embarrassing regulators. The Food and Drug
Administration rushed to approve Sovaldi, the argument goes, and then
Gilead goes and charges $84,000 per patient?
And Gilead, when it’s already going to be bringing in billions of
dollars a quarter, would be foolish to simply back down, not matter how
intense the criticism....
Except that the stakes here are actually even higher. Sovaldi is a
potent drug by itself, but the real excitement is about using it as part
of an all-oral single-pill combination that would cure hepatitis C
patients without interferon and ribavirin. Analysts have speculated that
such a pill could cost $100,000 per patient.
No comments:
Post a Comment